Second Genome

Founded in 2009, Second Genome is a biotech company in the microbiome space. They discover and develop therapeutics and biomarkers using their proprietary platform.

Referred to us by Argot Partners, Second Genome had pivoted their business model in the past and was looking to focus investor attention on their current narrative.

We worked closely with Second Genome’s CBO, Susannah Cantrell, and her team to understand their corporate journey. We helped reframe their company’s story, emphasize their assets, and recognize their history as a strength.

Our team created a new presentation from scratch, updated their brand and modernized the existing logo, and built a website using conceptual graphics and interactive MOAs. These different components work together to demonstrate Second Genome’s depth and value as a company.

“This looks amazing! What a difference from our current website. Pitch deck landing really well – have had several investor meetings and story is resonating.”

Susannah Cantrell, CBO

This slide details Second Genome's proprietary 'SG platform,' emphasizing data standardization, geographic diversity, and strain level analysis. It showcases various tools and capabilities within the platform, including TracerMix, PhyloChip, StrainSelect, KnowledgeBase, MAGE, MTMA, RoleModel, MPE, Pantastic, and Helios, for comprehensive microbiome analysis and therapeutic discovery.
This slide from Second Genome emphasizes the expanded definition of human biology to include the microbiome. It presents key statistics comparing the number of genes and cells in the human genome versus the human microbiome, highlighting the vast potential of studying microbial contributions to health.
his slide outlines Second Genome's therapeutic approach, focusing on microbial secretion. It illustrates how microbes release peptides that influence the human host and their process of identifying novel microbes, searching their genomes, identifying novel peptides, characterizing their mechanism of action, and identifying biomarkers.
This slide contrasts the traditional therapeutic approach focusing on microbial metabolites with the potential of new technologies to shift towards more precision therapeutic approaches with known target-mechanism biology, which is Second Genome's direction. It mentions common microbial metabolite therapies like fecal microbiota transplant, ecosystem therapeutics, and phage predation.
Responsive website design for Second Genome, showcasing their platform on a laptop, tablet, and mobile phone. The homepage highlights their mission of 'Discovering and developing transformational precision therapies' by 'extending the definition of what constitutes human biology' and leveraging the microbiome.
This image displays the 'Our Values' section of Second Genome's website across different devices. The values highlighted include being innovators, driven to action, great colleagues, respecting data, and working smart, contributing to their company culture in the microbiome research field.